The conjunction of clinical features, cell morphology and immunological characteristics allows an accurate diagnosis in most cases of B cell chronic lymphoproliferative disorders (CLD). However, the diagnosis remains uncertain in a small percentage of cases, often referred as to unclassified B cell proliferation or atypical chronic lymphocytic leukemia (CLL). We have studied retrospectively the 192 cases of leukemic CLD seen in our institution over a 3-year period, for which both clinical and routine biological data at presentation were available. Forty cases (20%) did not fit into any of the well-identified categories according to the FAB criteria and remained unclassified. We assessed cyclin D1 expression in all of these cases and found that 10 of them expressed a high level of cyclin D1 protein. We compared the characteristics of these 10 cases with those of the 30 cyclin D1 negative CLD. Despite non-distinctive cytological and phenotypic features, the 10 cyclin D1 positive patients exhibited a strikingly uniform clinical presentation with elevated leukocytosis, massive spleen enlargement and no superficial lymphadenopathy. Their outcome was very poor with a median survival of 10 months, contrasting with the prolonged survival of the cyclin D1 negative patients. The cytological features of tumor cells from these 10 patients with cyclin D1 positive unclassified leukemic CLD were similar to those of the circulating lymphoid cells from 15 patients with histologically proven mantle cell lymphoma (MCL) and primary or secondary blood involvement. Therefore, cyclin D1 expression allowed identification among the unclassified CLD, a subset of aggressive disorders which represent a leukemic counterpart of MCL (mantle cell leukemia). We suggest that determination of cyclin D1 expression by any technique available should be systematically included when investigating atypical CLL.
Introduction
B cell chronic lymphoproliferative disorders (CLD) represent a frequent diagnostic issue in hematological practice. In most cases, the conjunction of clinical presentation, cell morphology, and immunological characteristics allows an accurate diagnosis. Most of the chronic leukemic lymphoproliferative disorders fit into one category of the FAB classification, 1 such as chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), CLL-prolymphocytic leukemia, splenic lymphoma with villous lymphocytes (SLVL) or hairy cell leukemia (HCL). Leukemic phases of non-Hodgkin's lymphomas, such as mantle cell lymphoma (MCL) or follicular lymphoma (FL) may be strongly suspected on cytologic and immunologic criterias, but histological analysis of lymph node material is still required to ascertain the diagnosis.
In some instances, and particularly when no lymph node tissue is available, CLD remain unclassified and are referred to as atypical B cell proliferations or atypical CLL. Most of the Correspondence: F Ajchenbaum-Cymbalista; Fax: 33 1 42 34 82 54 Received 7 January 1998; accepted 20 April 1999 studies conducted on atypical B-CLL have been devoted to their immunologic characteristics 2, 3 or to cytogenetic abnormalities, [4] [5] [6] [7] [8] [9] [10] [11] but clinical presentation and outcome have not been extensively studied, although they are considered as sharing a poorer prognosis than typical CLL. 12 Among the recurrent genetic alterations observed in B-CLD, the translocation t (11;14) has been recently highlighted, since it is the hallmark of MCL. By bringing cyclin D1 gene (CCND1) located on chromosome 11q13 under the enhancer of IgH gene on chromosome 14q32, this translocation results in the abnormal expression of cyclin D1 protein in lymphoid cells which do not express this protein physiologically. [13] [14] [15] Cyclin D1 overexpression has also been observed with various levels in some cases of non-MCL lymphoproliferative disorder, such as HCL, 16, 17 SLVL, 18 PLL 19, 20 and occasionally atypical CLL. 19 We have assessed the expression of cyclin D1 protein in the circulating lymphoid cells from patients with poorly defined CLD, in order to evaluate its frequency in these difficult cases and its clinical and prognostic relevance.
We showed that overexpression of cyclin D1 identifies a subset of leukemic CLD characterized by a unique clinical presentation and a very poor outcome, and we suggest that the assessment of cyclin D1 expression should be included in the initial diagnosis procedure of atypical lymphoproliferative B cell disorders.
Materials and methods

Patient selection
We have retrospectively reviewed the clinical and biological data at presentation of 192 patients who underwent complete routine procedure including blood smear cytological analysis and peripheral blood immunophenotyping for a leukemic CLD over a 3-year period (1994) (1995) (1996) . Most patients had a newly diagnosed CLD but some had a previously known CLD at the time the complete evaluation was done. Peripheral blood for additional tests was obtained after informed consent. The diagnosis of leukemic B-CLD relied on the presence of over 4 × 10 9 /l circulating lymphoid cells with CD19 or CD20 positivity and immunoglobulin light chain restriction by cytometry. Patients with IgM monoclonal gammapathy exceeding 5 g/l were considered as having Waldenströ m's macroglobulinemia and were excluded from the study. All patients enrolled in the study, whether they were newly diagnosed or not, were followed in the same institution.
Clinical charts of patients were reviewed and the following data analyzed: age, gender, performance status, presence of superficial lymphadenopathy, spleen and/or liver enlargement, and presence of extra nodal disease. Subsequent laboratory findings were also collected: WBC and lymphocyte counts, hemoglobin level, platelet count, LDH and ␤ 2 -microglobulin serum levels.
Morphological evaluation
Cell morphology was analyzed independently by two cytologists on May-Grü nwald-Giemsa-stained peripheral blood smears. Patients were categorized into groups according to the FAB recommendations. 1 The following criteria were reviewed: cell size, nuclear/cytoplasmic ratio, density of chromatin, presence of nucleoli, nuclear shape, cytoplasmic features, and percentage of prolymphocytes.
Immunologic evaluation
Phenotype was assessed by flow cytometry on a BectonDickinson three color Facsort, using the following combinations of antibodies for the first step of diagnostic evaluation: CD20/CD5/DR, CD10/CD22/CD19, CD23/lambda/CD19, FMC7/kappa/CD19. Antibodies were directly labelled with fluorescein isothiocyanate (FITC), phycoerythrin (PE) and peridinin chlorophyll (PERCP), respectively. If after the first analysis step, the phenotype was not that of a typical CLL, additional antibodies were used for a second step analysis: CD11c, CD25, CD79b, slgM, slgG, slgD, using a two-color immunotyping, each of the above antibodies being tested in combination with a B cell marker such as CD19 or CD20. Antibodies against CD10, CD19, CD20, CD22 and CD25 were obtained from Becton Dickinson (Becton Dickinson, Immunocytosystem, San Jose, CA, USA). CD23, FMC7 were purchased from Immunotech (Marseille, France) and antibodies to kappa and lambda light chains from Dako (Dako, Trappes, France).
Cells were considered as positive or negative for a given antigen when у30% or Ͻ30% respectively of the B cell population were stained by the corresponding antibody. Assessment of intensity was based on the mean fluorescence intensity (MFI) of the cell population considering bright as у100 and dim as Ͻ100. We used the guidelines proposed by Matutes et al 3 for scoring lymphoid disorders, and accordingly considered as typical CLL the cases with score 4 and 5 in the presence of a characteristic morphology.
Cytogenetic analysis
Peripheral blood was incubated at 37°C for 72 h in presence of tetradecanoyl phorbol acetate (TPA) and lipopolysaccharide (LPS). Chromosome preparations were made by standard methods and were analyzed with R-or G-banding. Karyotypes were described according to ISCN. 21 Cyclin D1 protein expression analysis 10 ml of peripheral blood was obtained from patients after informed consent. Blood mononuclear cells were isolated by Ficoll-Hypaque density gradient. Samples of 10 7 cells were stored frozen as dry pellets at −80°C.
Protein extract:
10 7 cells were lysed in buffer (Tris 20 mm pH 8, NaCl 150 mm, Triton-X 100 1%, EDTA 5 mm, Na orthovanate 1 mm, NaF 10 m, leupeptin 10 g/ml, aprotinin 10 g/ml, PMSF 100 g/ml) for 20 min at +4°C. Lysates were spun at 10 000 g for 15 min and supernatants collected. Protein concentration was assessed by the BioRad assay method (BioRad Laboratories, Richmond, CA, USA). Protein extracts were either used immediately for Western blotting or frozen at −70°C.
Western blotting:
One hundred g of protein extracts were separated by 12% SDS polyacrylamide gel electrophoresis and transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA). Membranes were blocked for 1 h in 5% non-fat dry milk-PBS and incubated with anti-D1 antibody. Subsequently, filters were washed twice in Tris 10 mm pH 7.5, NaCl 200 mm and Tween 0.05%, and incubated with an appropriate horseradish peroxidase-linked secondary antibody at a 1:10 000 dilution for 1 h. Membranes were washed three times in the same rinsing buffer, and detection was performed by enhanced chemoluminescence protocol (ECL, Amersham, Bucks, UK) according to the manufacturer's recommendations.
Competitive RT-PCR for cyclins D expression
Competitive RT-PCR was performed as described by Uchimaru et al. 22 The upstream primer, named D1S, (5ЈCTG-GCCATGAACTACCTGGA-3Ј) is shared in amplification of the three D-type cyclin sequences and corresponds to an identical region between cyclin D1, D2, and D3 sequences nucleotides 385 to 404 in the sequence of cyclin D1, nucleotides 256 to 275 in cyclin D2 and nucleotides 403 to 422 in cyclin D3, while the downstream primers, D1AS (5Ј-GTCACACTTGAT-CACTCTGG-3Ј), D2AS (5Ј-CATGGCAAACTTAAAGTCGG-3Ј), and D3AS (5Ј-CCAGGAAATCATGTGCAATC-3Ј) are specific to their respective D-type cyclin sequences and correspond respectively to nucleotides 867 to 848 for cyclin D1, 609 to 590 for cyclin D2, and 649 to 630 for cyclin D3. Aliquots of 2 g total RNA were subjected to RT-PCR as described. Briefly, aliquots were placed in 20 l of 1 × RT buffer containing 10 mmol/l Tris-HCl, 50 mmol/l KCl, 4 mmol/l MgCl 2 , 10 mmol/l dithiothreitol, pH 8.3, 250 mol/l, 200 mol/l of each deoxyribonucleoside triphosphate, 100 ng hexamers, 20 U RNasin ribonuclease inhibitor, 100 U M-MLV reverse transcriptase (BRL). The reaction mixture was incubated at 37°C for 30 min and 1/10 of the reaction mixture subjected to subsequent PCR (PCR buffer: 10 mmol/l Tris-HCl, 50 mmol/l KCl, 1.5 mmol/l MgCl 2 , pH 8.3, 200 mol/l of each deoxyribonucleoside triphosphate, 0.2 mol/l of each primer, and 1 U recombinant Taq DNA polymerase). Thirty-five cycles of amplification (94°C: 30 s, 51°C: 45 s, and 72°C: 60 s), were conducted on a thermocycler. Aliquots of PCR products were electrophoresed on a 1% agarose gel, expected size of cDNA being 482 bp for cyclin D1, 353 bp for cyclin D2 and 243 bp for cyclin D3.
Statistical methods
Overall survival was calculated from the date of diagnosis until the patient's death or last visit. Actuarial survival probability curves were analyzed and plotted according to the method of Kaplan and Meier 23 and compared using the logrank test. 24 Differences in the distribution of variables between groups were determined using the Pearson's chi-squared test or the Fisher's exact test for categorical data, and the nonparametric Mann-Whitney test for continuous data.
Results
Study cohort
Based on clinical presentation, cell morphology and immunologic pattern of the circulating lymphoid cells, and according to the FAB guidelines, an accurate diagnosis was possible for 134/192 patients (70%). Typical CLL accounted for 59% of cases (n = 113), HCL for 7% (n = 14), PLL for 2% (n = 4) and SLVL for 1.5% (n = 3). Fifty-eight patients (30%) remained not strictly diagnosed ( Figure 1 ). In 25 of them, there was no peripheral lymphadenopathy. Among the 33 out of 58 patients presenting with peripheral lymphadenopathy, histological analysis of a biopsied lymph node led to the diagnosis of MCL in 15 patients and of small cell follicular lymphoma in three patients. Among the 15 MCL patients with leukemic features, eight were previously diagnosed and blood involvement occurred during the study period, while seven presented initially with blood involvement.
Therefore, the diagnosis remained unclear for 40 patients (20%) of our cohort. Fifteen of them had peripheral lymphadenopathy but histology, when done, was not clearly contributive, and 25 had no superficial lymphadenopathy. Twenty-two patients were newly diagnosed and 18 were previously recognized as having B-CLD, not otherwise specified. We focused our study on these 40 difficult cases and assessed cyclin D1 expression in all of them, as well as in the 15 MCL with blood involvement and in 50 cases of typical B-CLL.
Figure 1
Study cohort. Selection of the patients for which D1 analysis was performed. In addition, 50 among the 113 B-CLL cases were tested as a control. The 30 D1
− cases consist of 15 strictly leukemic CLD cases and 15 CLD cases with lymphadenopathy.
Expression of cyclin D1 protein
As this study concerned only leukemic patients, cyclin D1 was always assessed on blood samples. Among the 40 cases of unclassified CLD, expression of cyclin D1 protein expression was found by Western blotting in 10, subsequently referred to as cyclin D1 positive CLD (D1 + CLD), while the others are referred as to cyclin D1 negative CLD (D1 − CLD). Circulating tumor cells from all the 15 MCL patients expressed a strong level of cyclin D1 protein, but cyclin D1 could not be detected in any of the 50 CLL samples tested. The intensity of cyclin D1 expression in D1 + CLD samples was roughly similar to that of MCL samples, and no abnormal protein migration pattern was observed.
Cyclin D1 mRNA expression
When samples were available, cyclin D1 expression was also assessed at the RNA level by competitive RT-PCR, as described by Uchimaru et al. 22 This technique was performed on 7/10 D1 + CLD, 10/15 MCL, 15/30 D1 − CLD and 20 CLL samples. In all the cases that were found to express cyclin D1 protein (ie 7 D1 + CLD and 10 MCL), RT-PCR allowed the detection of cyclin D1 RNA. Conversely, all the cases negative by Western blot were also negative at the RNA level. Therefore, there was no discrepancy between the two techniques for diagnostic purposes.
Comparison of D1
+ and D1 + CLD patients presented consistently with a massive spleen enlargement found in nine of 10 patients (P = 0.003). There was no difference between the D1 + and D1 − CLD groups with regard to age, sex, presence of B symptoms, PS, liver enlargement and extranodal involvement.
The leukocyte count and the absolute number of circulating lymphoid cells were significantly higher in the D1 + CLD group than in the D1 − CLD group, as well as the ␤ 2 -microglobulin serum level. There were no difference between these two groups with respect to LDH, hemoglobin and albumin levels nor for the platelet count.
Cytological and immunological data:
There were no definite cytological criteria that allowed discrimination between D1
+ and D1 − CLD, even when the slides were reviewed retrospectively with the results of cyclin D1 assay. Morphological aspects were heterogenous in both groups, as illustrated in Figure 2 . In most cases, cells appeared of medium size with relatively mature chromatin, irregular nuclei and presence of inconspicuous nucleoli. In both groups, there were few cases showing much larger cells with more immature chromatin and marked nucleoli still distinct from prolymphocytes. We did not detect any cell with a blastic morphology. Among these 40 cases none appeared to have cytoplasmic expansion. Immunologic data are summarized in Table 2 . There was no significant difference in the immunologic profile between the D1 − and D1 + CLD groups. In both 
Figure 2
Morphological aspects of D1 + and D1 − patients. A and B, D1 + CLD patients; C and D, D1 − patients. groups, peripheral lymphoid cells consistently expressed CD5 and pan-B (CD19 and/or CD20) antigens and in most cases FMC7. Most of the cases were CD23 negative. According to Matutes scoring system, 3 all reached at most a score of 3, discriminating these patients from phenotypically typical CLL. In the D1 + CLD group, the cells consistently showed strong surface immunoglobulin expression whereas in the D1 − CLD group, nine of 24 patients had a weak surface immunoglobulin labelling. All cases but one D1 + CLD case were CD10 negative. Therefore, neither morphological analysis nor immunological profile of circulating lymphoid cells allowed discrimination between the D1 + and D1 − CLD samples.
Cytogenetic data:
Peripheral blood karyotype was available for all the 10 D1 + CLD patients and for 17/30 D1 − CLD patients. The complete karyotypes of the 10 D1
+ CLD patients are given in Table 3 , and comparative cytogenetic data are summarized in Table 4 . As expected, among the 10 D1 + CLD cases, nine had a t(11;14)(q13;q32) and the remaining D1 + patient had a del(11)(q13) and add(14)(q32). In the D1 − CLD group, a t(11;14)(q13;q32) was never observed.
All but one D1 + CLD case showed complex karyotype as opposed to less than 50% in the D1 − CLD patients (P = 0.003). Five D1 + CLD cases had an abnormality involving the short arm of chromosome 1 at different loci: add(1)(p34), del(1)(p22), del(1)(p22p32), del(1)(p32), t(1;21)(p34;p11). A trisomy 12 was found in three D1 46, XX, del(1)(p32), del(6)(q22), del(7)(q22), add(9)(p24),t(11;14)(q13;q32) [7] . Pt 9 43,XX, −9, add(10)(q26), −11, −13, der(14) t(11;14)(q13;q32), −17, −22,+mar [3] . Pt 10 46, XY, t(11;14)(q13;q32) [14] /46, XY [4] .
Outcome:
All the D1 + CLD patients required therapy within 1 month from diagnosis, while one third of the 30 D1 − CLD patients have not received any treatment so far, considering the absence of symptoms and the indolent evolution. Front-line treatment consisted of oral chemotherapy, anthracyclin-based chemotherapy or radiotherapy. Among the D1 + CLD patients, only two experienced a good response to treatment but they relapsed 57 and 25 months later, and finally died from disease progression at 66 and 65 months, respectively (Table 5) .
Conversely 
Comparison of the D1
+ CLD with leukemic MCL
We compared the clinical and biological data of the 10 D1
+ CLD patients and of the 15 MCL patients with blood involvement, either primarily or secondarily during the course of the disease. Almost all MCL patients (13/15) had peripheral lymphadenopathy and half of them had extranodal disease (gastrointestinal tract: four, tonsil: two, skin: one). The spleen was also less often enlarged (Table 1a) . No extensive Gl tract involvement was found in the D1 + CLD patients, but only five of them have been explored. D1 + CLD cases were also characterized by higher leukocyte and lymphoid tumor cell counts and a higher ␤ 2 -microglobulin serum level (Table 1b) . Morphology of circulating tumor cells from MCL patients was as heterogeneous as observed for the D1 + CLD patients and there was no distinctive immunologic pattern between these two groups. Four out of the 13 MCL cases with available karyotype had no detectable cytogenetic abnormality despite the fact they expressed cyclin D1 protein. Abnormalities involving chromosome 1p were observed in both D1 + CLD and MCL cases. The median overall survival from diagnosis of the 15 MCL patients was 60 months, significantly longer than that of the D1 + CLD patients (P = 0.03). However, when survival of the MCL patients was calculated from the time when blood involvement was evidenced, the difference between these two groups was no longer significant (Figures 3 and 4) . P values were calculated using the 2 or Fisher's exact test.
Table 5
Results CR, complete remission; PR, partial remission. Among the MCL cases, one patient died before initiation of treatment, and therefore appears in both 'no treatment' and 'not evaluable' categories.
Figure 3
Overall survival from the time of diagnosis. Median survival is 10 months for the D1 + CLD patients, 60 months for the MCL patients, 110 months for the D1 − CLD patients and 115 months for the CLL patients. Survival is statistically different between the D1 + CLD and MCL cases (P = 0.03). It is also significantly different between D1 + and D1 − CLD cases (P Ͻ 0.001). Survival is similar for D1 − CLD and CLL cases.
Discussion
Chronic leukemic lymphoproliferative disorders represent a variety of entities including typical CLL and other more or less indolent diseases, each of them having at least some specific biological characteristics. Clinical and cytological analysis are the cornerstone of the diagnosis procedure, usefully com-
Figure 4
Overall survival of the D1 CLD patients from the time of diagnosis and of the MCL patients from the time of diagnosis and from onset of blood involvement. There is a significantly different survival of D1
+ vs MCL patients (P = 0.03), but this difference disappears when considering survival of the MCL patients from onset of the leukemic phase.
pleted by the study of surface membrane antigens, histology of lymph node tissue when possible and cytogenetics. Depending on the number of these investigations performed, a variable percentage of leukemic lymphoproliferative disorders remains unclassified. 25 We have retrospectively analyzed all the cases of leukemic CLD seen in a single institution over a 3-year period, for which clinical and biological data at presentation, as well as outcome were available. Although it was not intended to be an epidemiological study, we found as expected, a majority of patients with a typical B-CLL and some with easily recognizable categories of CLD such as HCL or SLVL. In 40 patients, accounting for 20% of our cohort study, the diagnosis could not be formally established after cytologic and immunophenotypic analysis. In these cases, histological analysis of a bone marrow specimen did not provide further helpful information for classification purpose. All these cases were assessed for cyclin D1 expression and 10 of them were found to express high levels of cyclin D1 protein. This group of cyclin D1 + CLD was compared with the 30 remaining cyclin D1 − CLD cases and with 15 cases of histologically proven cyclin D1
+ MCL with blood involvement seen during the same period. Routine cytology and phenotypic analysis did not allow discrimination between D1 + and D1 − CLD cases and the only clear cut biological difference between these two groups was the presence of cyclin D1 expression. The morphological aspect of tumor cells on blood smears was variable among each group, as well as among the MCL group, ranging from small cleaved lymphoid cells with mature enough chromatin and inconspicuous nucleoli to larger cells with immature chromatin, distinct nucleoli and plasmocytoid cytoplasm. Other authors have already pointed out such a morphological heterogeneity in atypical B-CLL and MCL. [26] [27] [28] Immunophenotyping was not contributive except for confirming that none of these cases could be considered as typical B-CLL, which was already suggested by the morphology of tumor lymphoid cells in most cases. In nine of 10 cases, the cyclin D1
+ tumor cells exhibited a CD5
− phenotype consistent with MCL, but this phenotypic pattern was also shared by the tumor cells of most of the cyclin D1 − CLD. In contrast to their non-distinctive cytological and phenotypic features, the 10 patients we sorted out on the basis of cyclin D1 overexpression had strikingly similar clinical presentation and outcome. They all presented with high leukocytosis and spleen enlargement, often massive, and did not have peripheral lymphadenopathy. Their outcome was consistently very poor, even after therapy with anthracyclincontaining regimen, with a median overall survival of 10 months, while the patients with cyclin D1
− unclassified CLD had a survival estimate close to that of patients with typical B-CLL.
Nowadays, the presence of a translocation t (11;14) or the demonstration of cyclin D1 overexpression whatever the techniques used, indicate the diagnosis of MCL. [29] [30] [31] We did not find any distinctive morphological or immunologic characteristics between the circulating tumor cells of our 10 D1 + CLD and those of the 15 histologically proven MCL case with blood involvement. Disease outcome appeared worse for the D1 + CLD patients than for MCL patients, but this did not retain statistical significance when survival curves were drawn from the time when blood involvement was first noticed in MCL patients. In most studies in which it has been looked at, the presence of initial leukemic features in MCL represented an adverse prognostic parameter. 28, [32] [33] [34] [35] We asked whether this poor prognosis was linked to the presence of cyclin D1 overexpression. Overexpression of cyclin D1 has been reported in various CLD, namely PLL, 20, 36 atypical CLL 29 and even typical CLL. 37 Some of these reports are already a few years old and it is difficult to tell how many cases would be classified now in the same category as initially. Over a number of years, an increasing number of CLD are included within the MCL category. Whether the presence of a t(11;14) and/or cyclin D1 overexpression leads to consider a case as a bona fide MCL when no lymph node material is available, remains highly controversial 13, [38] [39] [40] and beyond the scope of this study. One should keep in mind that there are genuine non-MCL CLD that have been described to carry a translocation t (11;14) , such as SLVL in as much as 20% of cases. 18 In this disorder the resulting cyclin D1 overexpression does not appear to bear an adverse prognostic significance. 41 As previously reported in MCL, 42 most of our MCL cases with contributive cytogenetics and all but one of our D1 + CLD harbored complex karyotypes. It is noteworthy that abnormalities involving the short arm of chromosome 1 are recurrently observed in our cases, both in MCL and D1 + CLD. Even though these abnormalities span over a large chromosomal region, they might represent secondary genetics events responsible for a worsened prognosis. 43, 44 Should the D1 + CLD cases characterized by a predominant leukemic presentation with prominent splenomegaly be considered as part of the clinical spectrum of MCL, as it has recently been the case for the gastrointestinal presentation previously referred to as lymphomatous polyposis? 45 These D1 + CLD fit at best with the denomination of mantle leukemia that has already been proposed by some authors in the recent literature. 37, 46 But, beyond nosographic considerations, the major issue is to sort these D1 + CLD from all the CLD, and to look for cyclin D1 overexpression, although their early diagnosis does not lead to specific therapeutic guidelines at the present time. We have assessed cyclin D1 expression on blood samples using both Western blotting and competitive RT-PCR. In our hands, both techniques were reproducible and yielded similar results without any discrepancy. They have the same level of sensitivity that we estimated to approximately 5% of tumor cells. Immunohistochemistry is now a sensitive technique widely used on paraffin-embedded tissues, but is much less reproducible on bone marrow biopsy specimens. Therefore this technique is less suitable for strictly leukemic patients. Conventional cytogenetics is less effective in detecting the t(11;14) for identifying these patients, but it is likely that in situ hybridization produces results very close to the direct cyclin D1 assay.
A variable percentage of chronic leukemic lymphoproliferative disorders remains poorly defined after careful cytological and immunologic evaluation, and are often referred to as atypical CLL. With the help of cytogenetics and the various cyclin D1 expression assays, some of these poorly defined cases may be related to MCL. These mantle cell leukemia cases are characterized by both a high leukocyte count and prominent splenomegaly, as well as by a very poor outcome whatever the therapy proposed. Although their recognition does not yet lead to a specific therapeutic approach, we suggest that assessment of cyclin D1 should be included in the diagnostic procedures of atypical CLL. 47 
